Gland Pharma Reappoints Naina Lal Kidwai as Independent Director for Second Term
New Delhi: Gland Pharma Limited has approved the re-appointment of Naina Lal Kidwai as an Independent Director for a second term of five consecutive years from May 17, 2026 to May 16, 2031.
The decision was taken by the Board of Directors at its meeting held on April 9, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Kidwai had earlier been appointed as an Independent Director for a five-year term from May 17, 2021 to May 16, 2026, and her re-appointment ensures continuity in leadership and governance at the company.
A seasoned industry leader, Ms. Kidwai currently serves as Chairman of Rothschild & Co India and holds advisory roles with Advent Private Equity, TPG Rise Climate, and Lightspeed Venture Partners. She is also a Non-Executive Director on the boards of multiple leading companies including Holcim, Gland Pharma, UPL, and Biocon, and is a former President of FICCI.
She previously served as Executive Director on the Board of HSBC Asia Pacific and Chairman of HSBC India until her retirement in 2015, and later stepped down from the global board of Nestle in 2018.Kidwai is associated with several prestigious institutions, including the Indo-ASEAN Business Council, Harvard Business School’s South Asia Advisory Board, and Standard Chartered Bank’s International Advisory Council.
An MBA graduate from Harvard Business School, she has been honoured with the Padma Shri for her contribution to trade and industry. She has also authored books such as “30 Women in Power: Their Voices, Their Stories” and “Survive Or Sink: An Action Agenda for Sanitation, Water, Pollution, and Green Finance.”
Her work spans key areas such as sustainability, water, sanitation, and women empowerment. She currently chairs FICCI’s Water Mission and Sustainability Council and is the Founder and Chair of the India Sanitation Coalition, along with being associated with multiple global environmental and policy initiatives.
The company clarified that there are no inter-se relationships between the director and other board members and no additional disclosures are required under relevant SEBI circulars.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.